Indian health insurers are lobbying the IRDAI for specific guidance on multi-year policy commissions and expense-of-management limits following the close of recent consultations. The industry is concerned that the proposed framework may create accounting friction and pressure profit margins for standalone health providers compared to general insurers. Investors are tracking these updates as the regulator finalizes guidelines expected for implementation by April 2027.
The Indian health insurance sector is currently engaging in a critical dialogue with the Insurance Regulatory and Development Authority of India (IRDAI) regarding a proposed overhaul of distribution and expense-management frameworks. With the consultation period for the draft guidelines concluding on October 31, 2026, industry players are seeking urgent clarifications that could significantly shape their operational costs and reporting practices in the coming years.
At the core of the industry's concern is the classification of multi-year health insurance products. Insurers have requested the regulator to define clearly whether subsequent years of a multi-year policy should be treated as fresh business or as a renewal for the purpose of paying intermediary commissions. Currently, the lack of a definitive stance creates accounting friction, as companies struggle to reconcile upfront commission payouts with the deferred accounting practices required for long-term policies. For firms with a high concentration of multi-year products, such as Star Health, this distinction is vital to ensure that financial reporting accurately reflects the nature of their revenue and liabilities.
Beyond commissions, standalone health insurers are challenging the proposed common expense-of-management (EoM) framework, which seeks to tighten expense limits to 20 percent over a five-year horizon, with an interim goal of 25 percent within two years. Standalone providers argue that a one-size-fits-all model does not reflect the structural realities of their business. These insurers contend that mandatory product lines, such as motor third-party insurance, crop insurance, and government-sponsored health initiatives, should be excluded from the EoM calculation base. Because these segments often operate without intermediaries, including them in the cost calculation distorts the expense metrics applied to their core retail health products. Executives warn that without these exclusions, standalone health entities could face a competitive disadvantage against larger general insurers who possess more flexible and broader premium portfolios.
As the regulator reviews over 650 submissions from stakeholders, the industry is bracing for a transformation in how distribution costs are handled. The move toward using gross direct premium income for EoM calculations is a notable shift that will impact how insurers manage their operating margins. If the final guidelines do not provide the requested relief, it could lead to potential pressure on intermediary revenue and profit margins, with some analysts highlighting the risk of business restrictions if firms cannot meet the mandated phased reductions in expense ratios.
The final framework is generally expected to take effect by April 2027. Investors and market observers are watching for the final notification from the IRDAI, which will serve as the primary indicator of how the regulator balances the push for lower distribution costs with the operational nuances of the health insurance business. The key monitorable remains whether the regulator will accommodate the structural differences requested by standalone health players, or if the industry will have to adapt its expense strategies to the new, stricter caps.